Sorafenib Treatment Of Advanced Kidney Cancer Efficacy And Safety Evaluation

Objectives:Renal cell carcinoma(RCC) are male genitourinary system ,which is one of the common malignant tumor, past the immune therapy and inefficiency of chemotherapy were not very good.Small molecular targeted drug to appear improved the curative effect of renal cell carcinoma. This study evaluated preliminarily sorafenib treatment of advanced metastatic renal cell carcinoma efficacy and side-effect of Nebuchadnezzar, further discussing sora phillips in the application of advanced kidney cancer and its treatment of advanced kidney values for targeting therapy offer more scientific and objective basis.Methods:Summerize some April 2007 - January 2011 outpatient surgical excision were not the late shift occurred after kidney cancer or kidney and 43 cases of patients after pathology confirmed for kidney all clear cell carcinoma, according to solid tumor evaluation criteria in solid tumors (RECIST) at least 1 place single diameter can be measured lesion (≧ 1cm), all use targeted drug therapy, including 24 patients for sorafenib group, the more than 19 to sorafenib + low doses interferon group, male 34 patients, female 9 cases, patients (median age 61 35-80) years old, expected surial≧ 3 months. All patients given sorafenib target 400mg 2 times a day with oral, interferon group added 300MU tertian subcutaneous every 2 days until tumor progression or appearing untolerance adverse reactions. 1 times every month effect assessment, every 2 months on a radiographic evaluation. The main outcome for objective response rate, progression-free surial (PFS), secondary end points for oerall surial (OS), adverse reaction rate. Results:Patients with sorafenib group, an average of 24 patients taking sorafenib 15 (7 ~ 48) months. Some relief (PR), 1 case stability (SD) 9 cases, progression of disease (PD), 1 case with death rate of 13 cases, objective ease 4.16% (1/24), disease control rates 41.7% (10/24). Follow-up by January 2011, patients were median PFS 15 (7 ~ 48) months, clinical benefit patients (including PR and SD), the median PFS reach 29 (22 ~ 48) months. 13 cases of death in patients with a OS12 months, including 11 patients died of disease progression, 1 patients died of lung bleeding, 1 patients died of abdominal bleeding. Sorafenib + interferon group (19 cases), average taking sorafenib and interferon 15 (6 ~ 21) months, some relief (PR), 1 case stability (SD) 18 cases, disease (PD) progress "in 0 case, objective remission rates adverse (1/19), disease control rates 100% (19/19). Follow-up by January 2011, median PFS 15 (6 ~ 21) months, clinical benefit patients (including PR and SD), the median PFS reach 29 (22 ~ 48) months. Two groups of major adverse reactions are decreased appetite, hair loss, fatigue, diarrhea, skin rashes, hand-food skin reactions , hypertension, liver damage, tinnitus, merchant, two groups of adverse reactions incidence and severity no obvious difference, P > 0.05.Conclusions:Sorafenib for patients with advanced kidney disease control has good curative effect, adding interferon group can improve disease response rate, and no obvious increase adverse reactions, two groups of patients presented with different degrees of adverse reactions, after symptomatic treatment all patients can tolerate the adverse reactions, and the most violent reaction in drug early to mid adverse reaction, and the basic disappearance and side effects relative systemic chemotherapy for light, patients can be more tolerance and use more security.